Literature DB >> 24871932

Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.

Sahil Gupta1, Irfan Ahsan, Naeem Mahfooz, Noureldin Abdelhamid, Murali Ramanathan, Bianca Weinstock-Guttman.   

Abstract

Multiple sclerosis (MS) is a chronic inflammatory-demyelinating disease of the nervous system. There has been mounting evidence showing that MS is associated with increased risk of osteoporosis and fractures. The development of osteoporosis in MS patients can be related to the cumulative effects of various factors. This review summarizes the common risk factors and physiologic pathways that play a role in development of osteoporosis in MS patients. Physical inactivity and reduced mechanical load on the bones (offsetting gravity) is likely the major contributing factor for osteoporosis in MS. Additional possible factors leading to reduced bone mass are low vitamin D levels, and use of medications such as glucocorticoids and anticonvulsants. The role of the inflammatory processes related to the underlying disease is considered in the context of the complex bone metabolism. The known effect of different MS disease-modifying therapies on bone health is limited. An algorithm for diagnosis and management of osteoporosis in MS is proposed.

Entities:  

Mesh:

Year:  2014        PMID: 24871932     DOI: 10.1007/s40263-014-0173-3

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  99 in total

1.  Opioid osteoporosis.

Authors:  Harry W Daniell
Journal:  Arch Intern Med       Date:  2004-02-09

Review 2.  Bone health in multiple sclerosis.

Authors:  J C Gibson; G D Summers
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507

3.  Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity.

Authors:  Salih Ozgocmen; Serpil Bulut; Nevin Ilhan; Arif Gulkesen; Ozge Ardicoglu; Yusuf Ozkan
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

Review 4.  Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.

Authors:  R N J De Nijs
Journal:  Minerva Med       Date:  2008-02       Impact factor: 4.806

5.  Bone strength in multiple sclerosis: cortical midtibial speed-of-sound assessment.

Authors:  Anat Achiron; Shmuel Edelstein; Y Ziev-Ner; Uri Givon; Zeev Rotstein; Yoram Barak
Journal:  Mult Scler       Date:  2004-10       Impact factor: 6.312

Review 6.  Neuromedin U: physiology, pharmacology and therapeutic potential.

Authors:  S Budhiraja; A Chugh
Journal:  Fundam Clin Pharmacol       Date:  2009-04       Impact factor: 2.748

7.  Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis.

Authors:  Linn Hofsøy Steffensen; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2009-10-01       Impact factor: 4.849

Review 8.  Pathophysiology of osteoporosis.

Authors:  R P Heaney
Journal:  Endocrinol Metab Clin North Am       Date:  1998-06       Impact factor: 4.741

9.  Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition.

Authors:  Mina C Mojtahedi; Erin M Snook; Robert W Motl; Ellen M Evans
Journal:  J Rehabil Res Dev       Date:  2008

Review 10.  Pharmacology and therapeutic potential of interferons.

Authors:  Peter M George; Rekha Badiger; William Alazawi; Graham R Foster; Jane A Mitchell
Journal:  Pharmacol Ther       Date:  2012-03-28       Impact factor: 12.310

View more
  12 in total

1.  Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.

Authors:  Lara Marie Pangan Lo; Bruce V Taylor; Tania Winzenberg; Andrew J Palmer; Leigh Blizzard; Ingrid van der Mei
Journal:  J Neurol       Date:  2020-09-03       Impact factor: 4.849

2.  Osteoporosis management and secondary fragility fracture rates in patients with multiple sclerosis: a matched cohort study.

Authors:  Bailey J Ross; Austin J Ross; Olivia C Lee; Timothy L Waters; McCayn M Familia; William F Sherman
Journal:  Osteoporos Int       Date:  2022-06-07       Impact factor: 5.071

3.  Propionic acid beneficially modifies osteoporosis biomarkers in patients with multiple sclerosis.

Authors:  Alexander Duscha; Tobias Hegelmaier; Kerstin Dürholz; Christiane Desel; Ralf Gold; Mario M Zaiss; Aiden Haghikia
Journal:  Ther Adv Neurol Disord       Date:  2022-06-21       Impact factor: 6.430

4.  Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.

Authors:  Lars G Hvid; Egon Stenager; Ulrik Dalgas
Journal:  J Neurol       Date:  2022-04-28       Impact factor: 6.682

Review 5.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

6.  Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study.

Authors:  Cecilia Smith Simonsen; Elisabeth Gulowsen Celius; Cathrine Brunborg; Chantal Tallaksen; Erik Fink Eriksen; Trygve Holmøy; Stine Marit Moen
Journal:  BMC Neurol       Date:  2016-12-05       Impact factor: 2.474

7.  High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.

Authors:  Trygve Holmøy; Jonas Christoffer Lindstrøm; Erik Fink Eriksen; Linn Hofsøy Steffensen; Margitta T Kampman
Journal:  BMC Neurol       Date:  2017-04-04       Impact factor: 2.474

Review 8.  Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology.

Authors:  Alison Barry; Owen Cronin; Aisling M Ryan; Brian Sweeney; Siew M Yap; Orna O'Toole; Andrew P Allen; Gerard Clarke; Ken D O'Halloran; Eric J Downer
Journal:  Front Physiol       Date:  2016-06-02       Impact factor: 4.566

9.  Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.

Authors:  Umberto Tarantino; Giovanni Iolascon; Luisella Cianferotti; Laura Masi; Gemma Marcucci; Francesca Giusti; Francesca Marini; Simone Parri; Maurizio Feola; Cecilia Rao; Eleonora Piccirilli; Emanuela Basilici Zanetti; Noemi Cittadini; Rosaria Alvaro; Antimo Moretti; Dario Calafiore; Giuseppe Toro; Francesca Gimigliano; Giuseppina Resmini; Maria Luisa Brandi
Journal:  J Orthop Traumatol       Date:  2017-11

Review 10.  Factors influencing peak bone mass gain.

Authors:  Xiaowei Zhu; Houfeng Zheng
Journal:  Front Med       Date:  2020-06-09       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.